多西紫杉醇
吉西他滨
医学
内科学
化疗
肿瘤科
肺癌
耐火材料(行星科学)
毒性
进行性疾病
外科
胃肠病学
天体生物学
物理
作者
Sofia Agelaki,M. Veslemes,Kostas Syrigos,F Palamidas,Aristidis Polyzos,Pavlos Papakotoulas,Nikolaos Kentepozidis,G. Milaki,Νikolaos Tzanakis,Charalambos Kouroussis,L. Vamvakas,Vassilis Georgoulias
出处
期刊:Lung Cancer
[Elsevier]
日期:2004-03-01
卷期号:43 (3): 329-333
被引量:16
标识
DOI:10.1016/j.lungcan.2003.08.031
摘要
To evaluate the efficacy and toxicity of the combination of gemcitabine and docetaxel in pretreated patients with small-cell lung cancer (SCLC).Twenty-two pretreated patients (median age 61 years, PS: 0-1 in 77% and 2 in 23%) with limited or extensive stage disease were treated with gemcitabine 1000 mg/m2 on days 1 and 8 and docetaxel 75 mg/m2 on day 8, every 21 days. Fifteen (68%) of the 22 patients had received two prior regimens and fourteen (64%) were refractory to front-line chemotherapy.All patients were evaluable for efficacy analysis. No complete or partial responses were observed. Disease stabilization was obtained in one (5%) patient. The median survival was 14 weeks and the six-month survival rate was 28%. WHO grade 2 and 3 toxicities were infrequent and easily manageable.The combination of gemcitabine and docetaxel was inactive as salvage treatment in this poor prognosis group of patients with SCLC.
科研通智能强力驱动
Strongly Powered by AbleSci AI